Obesity Abstracts

Background: Multidisciplinary care is well recognised as being effective for weight and chronic disease management, and in weight loss maintenance. However, in the Australian context, there are inadequate obesity services. In recognising this health service gap, this led to the establishment of the privately funded university hospital-based weight management clinic – the ‘Healthy Weight Clinic’ to increase access to multidisciplinary services. The effec...

Liraglutide 3 mg daily is an approved, prescription injectable GLP-1 receptor agonist, which can reduce weight in patients with obesity, with or without obesity complications. We conducted a 24-week, open-label real-world study involving 62 participants with a BMI >30 kg/m2 or >27 kg/m2 if they had co-existing dyslipidaemia or hypertension. No patients had type 2 diabetes. Patients received once-daily subcutaneous liraglutide 3.0 mg, alongside NHS...